NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$4,400.00
Cat.#: 11039 | ||
Product Name: Human CMTM6 Full Length Protein | ||
Size : 10 µg, 50 µg and 100 µg | ||
Synonyms: CKLFSF6; PRO2219 | ||
Target: CMTM6 (CKLF like MARVEL transmembrane domain containing 6, chemokine-like factor superfamily 6) | ||
UNIPROT ID: Q9NX76 | ||
Description: Human CMTM6 full length protein-synthetic nanodisc | ||
Background: CMTM6 belongs to the chemokine-like factor gene superfamily, a novel family that is similar to the chemokine and transmembrane 4 superfamilies. This gene is one of several chemokine-like factor genes located in a cluster on chromosome 3. CMTM6 is involved in the immune-related and metabolism-related pathways. It increases the expression of programmed cell death 1 ligand 1 protein, thereby impairing T cell function. Various manufactured therapeutic monoclonal antibody drugs, e.g. pembrolizumab, atezolizumab, durvalumab, nivolumab, and avelumab, bind to and inhibit the stimulation of PD-1 on CD8+ T cells by PD-L1. In effect, they block the ability of CMTMT6 to suppress PDL1/PD-1-stimulated CD8+ T-cell immune responses against tumor cells. Elevated expression of CMTM6 in glioma and head and neck squamous cell carcinoma was shown to be associated with a poor prognosis; in addition, CMTM6 is also a potential therapeutic target for triple-negative breast cancer. | ||
Species/Host: HEK293 | ||
Molecular Weight: The human full length CMTM6 protein has a MW of 20.4 kDa | ||
Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization. | ||
Storage & Shipping: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. | ||
|